Anne-Fabienne Weitsch, Laura Francis, Eric Lachenmeier

Hybrigenics has appointed Anne-Fabienne Weitsch to the position of chief operating officer, the Paris-based functional proteomics company said last week. Weitsch, who most recently served at Johnson & Johnson as senior director of licensing and business development, will be responsible for all aspects of Hybrigenics’ management, business development and drug discovery activities, the company said. Prior to Johnson & Johnson, Weitsch worked at the Janssen Research Foundation as senior director, collaborations and technology transfer, and at Zyma, a CIBA company, in a number of R&D positions.

Laura Francis has joined Bruker AXS as chief financial officer, the Madison, Wis.-based company said. Most recently, Francis served as CFO of start-up companies Hypercosm and Nutra-Park. Previously, she served as an engagement manager at McKinsey & Co. In addition to her duties as CFO, Francis will also be responsible for investor relations.

Aviva Biosciences has appointed Eric Lachenmeier director of business development, the San Diego-based biochip company said. In previous positions, Lachenmeier served as vice president for technology development at Incyte Genomics, and as an R&D project director and engineer at Lynx Therapeutics and Applied Biosystems.